News | Radiation Therapy | May 31, 2019

RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform

Facility includes six linear accelerator testing vaults for RefleXion BgRT system

RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform

May 31, 2019 — RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward, Calif. The 50,000 square-foot facility includes six state-of-the-art linear accelerator testing vaults for the RefleXion machine and will house manufacturing, quality control, and a customer education center with a radiation oncology suite for clinical training.

The new facility, which is the third building on the company’s campus, took 11 months to complete and required over 12 million pounds of concrete. In conjunction with the City of Hayward, RefleXion held an official ribbon-cutting ceremony on May 22.

RefleXion’s biology-guided radiotherapy (BgRT) platform is the first, according to the company, to utilize the cancer itself to guide radiation delivery, even in tumors that are moving. The patented technology uses positron emission tomography (PET), the gold standard in cancer staging, one day enabling multiple tumors to continuously signal their location during treatment. PET uses a tracer drug that is accumulated by the tumors and produces emissions illuminating their locations. The RefleXion machine detects the emissions and immediately sends beamlets of radiation directly to the tumor to destroy it.

For more information: www.reflexion.com

Related Content

IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Plan to attend RSNA21 at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | September 13, 2021
September 13, 2021 — The Radiological Society of North America (RSNA) today announced highlights of the Technical Exh
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
An artificial intelligence (AI) program can spot signs of lung cancer on computed tomography (CT) scans a year before they can be diagnosed with existing methods, according to research presented at the European Respiratory Society International Congress.

Diagram showing details of the lung screening experiment. Image courtesy of the European Respiratory Society/Benoit Audelan

News | Artificial Intelligence | September 08, 2021
September 8, 2021 — An artificial intell...
Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).
News | PET Imaging | September 03, 2021
September 3, 2021 — Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Maste